Ophthalmology Billing: Intravitreal Injections, Cataract Globals, and Premium IOLs in 2026

Why Ophthalmology Billing Is Different

Ophthalmology occupies an unusual space in revenue cycle management because it blends high volume outpatient surgery, chronic disease management, diagnostic imaging, and cosmetic-adjacent procedures into a single specialty. A single mid-sized retina or cataract practice can generate claims across cataract extraction (CPT 66984, 66982), intravitreal injections (CPT 67028) paired with high-cost drug J-codes, diagnostic imaging (92133, 92134, 92227, 92228, 92229), and routine eye exams (92002 to 92014) in the same week, each governed by different frequency limits, medical necessity policies, and bundling edits. Unlike primary care, where denials cluster around a handful of E/M coding errors, ophthalmology denials are distributed across surgical globals, drug administration bundling, laterality modifiers, and premium technology upgrades that Medicare will never cover.

The specialty's reliance on paired procedure and supply billing is a major complexity driver. Every intravitreal injection requires two correctly linked claim lines: the administration code (67028) and the drug J-code (J0178 for aflibercept, J2778 for ranibizumab, J0179 for brolucizumab, J2777 for faricimab), each carrying its own laterality modifier, units calculation, and medical necessity diagnosis. According to CMS Local Coverage Article A52451, claims for 67028 without the appropriate site modifier are returned unprocessed, and if the drug is denied as not reasonable and necessary, the associated injection code is denied as well, creating a compounding risk that most other specialties do not face at this frequency.

Global surgical periods add another layer that many ophthalmology coders find harder to manage than in other surgical specialties, because cataract patients frequently return for a second-eye surgery, YAG capsulotomy, or unrelated glaucoma and retina care within the 90-day global window of the first procedure. Distinguishing a related complication (modifier 78), a planned staged procedure (modifier 58), an unrelated procedure (modifier 79), and an unrelated E/M visit (modifier 24) requires granular documentation of medical decision-making that primary care visits rarely need. The American Academy of Ophthalmology coding resources and payer manuals consistently flag global period modifier misuse as a leading cause of denied or downcoded claims.

Finally, ophthalmology sits at the intersection of covered medical necessity and elective, patient-pay premium technology, which no other high-volume surgical specialty manages at the same scale. Multifocal, toric, and accommodating intraocular lenses (V2632 and related codes) are billed partly to Medicare for the covered cataract extraction and partly to the patient for the non-covered lens upgrade, requiring an Advance Beneficiary Notice, a clean split of professional fees, and scrupulous avoidance of billing the government for costs that are the patient's responsibility.

The 2026 Policy and NCCI Landscape for Ophthalmology

CMS Physician Fee Schedule and RVU Changes

The CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), released October 31, 2025 and effective January 1, 2026, introduced two separate conversion factors for the first time: $33.5675 for qualifying Alternative Payment Model (APM) participants and $33.4009 for non-qualifying participants, increases of 3.77% and 3.26% respectively over the 2025 conversion factor of $32.3465. CMS also finalized a new efficiency adjustment that cuts work RVUs by 2.5% for nearly all non-time-based procedural and diagnostic codes, based on a five-year lookback at the Medicare Economic Index productivity adjustment.

For ophthalmology specifically, this adjustment reduced the work RVU for CPT 66984 (routine cataract extraction with IOL) from 7.35 to 7.17, and combined with a reduction in facility practice expense allocation, cut the 2026 Medicare payment for 66984 to $462.94, an 11% decrease from the 2025 payment of $521.75, per ASCRS analysis. The American Medical Association reports that 54% of ophthalmologists face payment cuts under the combined efficiency adjustment and facility practice expense changes for 2026.

2026 NCCI Policy Manual, Chapter 8

The 2026 Medicare NCCI Policy Manual, Chapter 8, Section D (revision date January 1, 2026) governs the bulk of ophthalmology-specific bundling logic. Key 2026 rules include: cataract extraction codes (66830 to 66991) are mutually exclusive of one another, so only one cataract code may be reported per eye; intravitreal injection (67028) may not be reported with paracentesis (65800 to 65815) or subconjunctival injection (68200) at the same encounter; injections of antibiotic, steroid, or NSAID during cataract extraction are bundled and not separately reportable; and iridectomy, anterior vitrectomy, or trabeculectomy performed at the same encounter as cataract extraction is bundled unless it is separate and distinct for an unrelated reason, in which case an NCCI PTP-associated modifier (59 or the more specific X modifiers) is required with clear documentation of distinct medical necessity.

Prior Authorization in 2026

CMS finalized the Interoperability and Prior Authorization Final Rule (CMS-0057-F) with initial provisions effective January 1, 2026, requiring impacted Medicare Advantage, Medicaid, CHIP, and ACA marketplace payers to respond to standard prior authorization requests within 7 calendar days and expedited requests within 72 hours, and to provide a specific reason for every denial regardless of submission method. A related 2026 proposed rule would extend similar decision timeframes and denial-reason transparency to drug prior authorizations, including anti-VEGF intravitreal agents, with compliance proposed for October 1, 2027.

In the near term, anti-VEGF injections remain heavily gated by commercial and Medicare Advantage step therapy policies that require documented bevacizumab (Avastin) failure or contraindication before approving branded agents such as aflibercept (Eylea, J0178) or ranibizumab (Lucentis, J2778).

Diabetic Retinopathy Screening and Extended Ophthalmoscopy

Screening codes 92227, 92228, and 92229 remain subject to strict once-per-year frequency limits by Medicare Administrative Contractors, and multiple commercial payers exclude 92227 from separate reimbursement or bundle it into other services, so coders must verify local coverage determinations before billing more than one screening test per member per year. Extended ophthalmoscopy (92201, 92202) frequency limits also vary by diagnosis code under several commercial reimbursement policies, requiring diagnosis-specific frequency tracking rather than a single global limit.

Top 6 Ophthalmology Denial Patterns in 2026

Ophthalmology practices tend to see the same denial patterns repeatedly. Knowing the root cause behind each code, rather than just the code itself, is what separates a practice with a single-digit denial rate from one writing off 15% of gross charges. Here are the six most consistent patterns, with the CARC codes typically attached and the fastest path to resolution.

1. Missing or Mismatched Laterality Modifier on 67028 (CARC 4, CARC 16)

CARC 4 (procedure code inconsistent with modifier used) and CARC 16 (claim lacks information needed for adjudication) appear when a retina practice bills 67028 for a unilateral intravitreal injection but omits RT, LT, or 50, or applies mismatched laterality between the administration code and the drug line (J0178, J2778, J0179, J2777). CMS coverage policy explicitly states that claims for 67028 without the appropriate site modifier will be returned unprocessed, and both the administration line and the drug line each require their own anatomic modifier. A bilateral same-day injection billed as two separate lines with RT and LT on 67028, instead of a single line with modifier 50, is also a frequent rejection trigger for Medicare. Build a hard claim-scrubber edit requiring RT, LT, or 50 on every 67028 line before submission, and confirm the drug J-code line carries matching laterality.

2. Intravitreal Drug Denied Without Prior Authorization or Step Therapy (CARC 197, CARC 50)

CARC 197 (precertification, authorization, or notification absent) and CARC 50 (non-covered because not deemed a medical necessity) appear when a patient is switched from bevacizumab to aflibercept for wet AMD without documenting a trial and failure of the preferred first-line agent, or when the injection is administered before the payer's prior authorization is on file. Nearly all major commercial and Medicare Advantage plans require step therapy showing bevacizumab failure or contraindication before covering branded anti-VEGF agents, and authorization requested retroactively after a denial is rarely honored, per Retina Today's analysis of injection claim denials. Maintain a payer-specific prior authorization matrix noting which plans require step therapy and expected turnaround times, now bounded by the CMS 7-day standard and 72-hour expedited rule for impacted payers in 2026.

3. Complex Cataract (66982) Billed Without Complexity Documentation (CARC 50, CARC 16)

A surgeon reports 66982 for a cataract case with a small pupil, weak zonules, or use of iris hooks, but the operative note only states complicated case without describing the specific complexity factor and how it increased surgical difficulty. Payers require the operative note to name a qualifying complexity factor (small or bound pupil requiring four-quadrant iris retractors, pediatric cataract with primary capsulotomy and anterior vitrectomy, or capsular fixation devices for zonular insufficiency), and generic language does not meet that bar, per Envolve Vision complex cataract criteria. Require a standardized complexity attestation section in the operative template that names the specific technique used (iris retractors, capsular tension ring, trypan blue staining for poor red reflex) and links it to a preoperative finding.

4. Premium IOL Billed as a Covered Medicare Benefit (CARC 96, CARC 50)

CARC 96 (non-covered charges) appears when a practice bills Medicare for the full cost of a multifocal or toric premium lens rather than separating the covered monofocal-equivalent portion from the non-covered upgrade charged to the patient. Medicare's National Coverage Determination on intraocular lenses (NCD 239) explicitly states that Medicare does not pay for the additional cost of a multifocal, accommodating, or toric lens over a standard monofocal IOL; only the cataract extraction with standard IOL implantation is a covered procedure. Use an Advance Beneficiary Notice for the non-covered premium lens upgrade, split billing so the covered portion goes to Medicare and the upgrade cost is billed directly to the patient, and document informed financial consent before surgery.

5. Global Period Modifier Misuse Around YAG and Second-Eye Surgery (CARC 97, CARC 4)

CARC 97 (payment included in allowance for another service) appears when a YAG capsulotomy (66821) performed within 90 days of the original cataract surgery on the same eye is billed without modifier 79, or when a second-eye cataract surgery performed during the first eye's global period lacks modifier 79 and the LT/RT distinction. No modifier is required if YAG capsulotomy occurs more than 90 days after cataract surgery and the patient is not in any other global period; but if it falls within a global period for a related procedure it needs modifier 78, and if unrelated (different eye or unrelated condition) it needs modifier 79 with LT or RT, per AAPC guidance on YAG capsulotomy global periods. Track each patient's global period start and end dates by eye in the practice management system before selecting a modifier.

6. Diabetic Retinopathy Screening Billed Over Frequency Limits (CARC 119, CARC 96)

CARC 119 (benefit maximum for this time period reached) appears when a practice bills 92227 for retinal imaging screening more than once in a 12-month period, or bills 92227 or 92229 for a patient who has already had an in-person ocular examination by an ophthalmologist that year. Medicare Administrative Contractors will not pay for 92227 more frequently than annually, and once retinopathy is diagnosed, continued use of the screening code 92227 no longer applies because the patient's care is no longer screening in nature. Flag patient records for an existing diagnosis of diabetic retinopathy before scheduling a screening test, and route those patients to standard diagnostic imaging and E/M coding instead.

Documentation and Workflow Practices That Win

Ophthalmology billing problems are almost always documentation problems before they become billing problems. The following practices address the upstream clinical record issues that create the denial patterns above.

1. Name a specific complexity factor in every 66982 operative note. Use precise language such as 4 mm pupil requiring iris hooks or zonular dehiscence requiring capsular tension ring, never a generic phrase like complicated case. Ideally reference a preoperative finding, such as imaging, that predicted the complexity.
2. Record the full drug administration record for every intravitreal injection. Document the drug name, concentration, dosage administered, eye treated, and any wasted amount, so the J-code units and JW or JZ wastage modifier match the chart exactly.
3. Maintain a global period tracker by patient and eye. Flag the surgery date, the 90-day window end date, and any subsequent procedures or E/M visits scheduled inside that window, so the correct modifier (24, 58, 78, or 79) is chosen before the claim is coded.
4. Keep signed Advance Beneficiary Notices and financial consent on file for every premium IOL case. Itemize the covered monofocal-equivalent portion and the non-covered upgrade cost separately before surgery, and confirm both the surgeon and the patient signed the paperwork.
5. Require a specific clinical indication on every diagnostic imaging order. Codes 92133, 92134, 92227, 92228, 92229, 92250, 92201, and 92202 all need the specific clinical indication and diagnosis code that justifies medical necessity, not just a routine follow-up notation.
6. Verify laterality (RT, LT, or 50) on every unilateral or bilateral procedure line. Include both the procedure code and any paired drug or supply code. A pre-submission scrubber that rejects any 67028 line without an anatomic modifier prevents the single most common ophthalmology denial.
7. Document step therapy explicitly before initiating branded anti-VEGF therapy. Note the specific prior agent tried, the response or lack of response, and any contraindication, in language that mirrors the payer's own medical policy criteria.

Frequently Asked Questions

Why does Medicare keep denying our 67028 intravitreal injection claims even when we include the drug code?

The most common cause is a missing or mismatched laterality modifier (RT, LT, or 50) on the 67028 administration line, the drug line, or both. CMS Local Coverage Article A52451 states that claims for 67028 without the appropriate site modifier are returned unprocessed. This typically triggers CARC 4 or CARC 16. Confirm that both the administration and drug lines carry identical laterality before submission.

Can we bill both cataract extraction (66984) and an anterior vitrectomy on the same claim?

Only if the vitrectomy is separate and distinct from the cataract extraction for an unrelated reason, with distinct medical necessity documented in the operative note, and an NCCI PTP-associated modifier (59 or an X modifier) applied. Minimal vitreous loss during a routine cataract extraction is bundled and not separately reportable under the 2026 NCCI Policy Manual, Chapter 8.

What is the difference between modifier 78 and modifier 79 for a YAG capsulotomy after cataract surgery?

Modifier 78 applies to an unplanned return to the operating or procedure room for a related complication during the global period and does not restart the global clock. Modifier 79 applies to an unrelated procedure by the same physician during the postoperative period and does start a new global period. A YAG capsulotomy for posterior capsule opacification on the same eye within 90 days of cataract surgery, treated as related follow-up, is often bundled unless the payer requires modifier 78; if it is on the other eye or clearly unrelated, use modifier 79.

Why was our premium IOL claim denied by Medicare even though we billed the standard portion?

If V2632 or another premium lens HCPCS code is billed as if it were fully covered rather than split between the covered baseline allowance and the patient-billed upgrade, Medicare will deny the excess as non-covered under CARC 96, since NCD 239 explicitly excludes the additional cost of multifocal, toric, or accommodating lenses over a standard monofocal IOL.

How often can we bill diabetic retinopathy screening codes 92227, 92228, or 92229?

Generally once per 12-month period per payer policy. Medicare Administrative Contractors will not pay for 92227 more than annually, and 92227 or 92229 should not be billed once a patient has had an in-person ocular exam by an ophthalmologist in that period, since the visit is then diagnostic rather than screening. Repeated billing triggers CARC 119 for frequency limits.

What documentation do we need to justify 66982 instead of 66984?

The operative note must state the specific complexity factor (small or bound pupil requiring iris retractors, weak zonules requiring a capsular tension ring, pediatric cataract requiring primary capsulotomy, dense or hypermature lens, or similar) and ideally reference a preoperative finding, such as imaging, that predicted the complexity. General statements like difficult case are insufficient and commonly lead to a downcode to 66984 or an outright medical necessity denial (CARC 50).

Do we need prior authorization for every anti-VEGF injection?

It depends on the payer and the specific drug. Many commercial and Medicare Advantage plans require step therapy documentation of bevacizumab failure or contraindication before approving branded agents like aflibercept (J0178) or ranibizumab (J2778), while Medicare fee-for-service generally does not mandate step therapy for these drugs. As of 2026, impacted Medicare Advantage, Medicaid, and marketplace payers must respond to standard prior authorization requests within 7 days and expedited requests within 72 hours under the CMS Interoperability and Prior Authorization Final Rule.

Why is our comprehensive eye exam (92014) getting denied when we also billed an E/M code the same day?

Payers expect a practice to choose either the eye code family (92002 to 92014) or the E/M family (99202 to 99215) for a given encounter based on which set of documentation elements the visit actually supports, not to alternate between them to maximize payment. Billing both without a clearly separate, medically necessary reason typically triggers a bundling denial (CARC 97) since the two code sets describe overlapping physician work for the same encounter.

How ROI Addresses Ophthalmology Denial Patterns

Ophthalmology billing problems are systematic. The same laterality errors, the same step therapy gaps, and the same premium IOL split-billing mistakes appear across practices of all sizes. At Revenue Optimization & Intelligence, we built our denial taxonomy around specialty-specific patterns, and ophthalmology is one of the most consistently mapped because the code combinations that generate denials are predictable.

• The ROI platform ingests 835 remittance files from any clearinghouse or EHR export and flags CARC/RARC combinations specific to ophthalmology, including laterality modifier denials, anti-VEGF step therapy conflicts, and premium IOL split-billing errors, automatically routing each to the correct denial category.
• The EDI Code Intelligence Lab includes entries for every CARC and RARC code commonly seen in ophthalmology, each with fix, appeal, and prevention guidance written for billing staff who need to act on a denial today rather than read a policy manual.
• Our appeal template library includes ophthalmology-specific templates for intravitreal injection denials, complex cataract downcoding appeals, and premium IOL split-billing frameworks with clinical documentation language built in.
• Take the free Revenue Health Assessment to see how your ophthalmology denial rate compares to specialty benchmarks and where the fastest recovery opportunities sit in your current claim mix.

"Ophthalmology billing rewards practices that build laterality and global period discipline into the front end. Every unprocessed 67028 claim is preventable at the scrubber. Every premium IOL split is knowable before the surgery date. A denial in this specialty is almost always something that could have been caught before the claim ever went out." Mindy Corbett, CSPO, CPC, CPB, CPPM, Founder, Revenue Optimization & Intelligence

Sources

1. Centers for Medicare & Medicaid Services. Medicare NCCI 2026 Coding Policy Manual, Chapter 8: Surgery, Integumentary, Musculoskeletal, Respiratory, and Ophthalmology. https://www.cms.gov/files/document/08-chapter8-ncci-medicare-policy-manual-2026-final.pdf
2. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule Fact Sheet (CMS-1832-F). https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
3. ASCRS. 2026 Medicare Physician Fee Schedule Final Rule Released. https://www.ascrs.org/news/ascrs-news/2026-medicare-physician-fee-schedule-final-rule-released
4. American Medical Association. What to Expect from the 2026 Medicare Physician Fee Schedule. https://www.ama-assn.org/practice-management/medicare-medicaid/what-expect-2026-medicare-physician-fee-schedule
5. Centers for Medicare & Medicaid Services. CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F). https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f
6. Centers for Medicare & Medicaid Services. Local Coverage Article A52451: Billing and Coding, Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbll, Faricimab-svoa. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52451&ver=86
7. PayerPolicy. CMS NCD 239: Intraocular Lenses (IOLs) Coverage Update. https://payerpolicy.org/updates/cms/cms-ncd-239-intraocular-lenses-iols-coverage-update
8. Retina Today. Why Was My Intravitreal Injection Claim Denied? https://retinatoday.com/articles/2021-jan-feb/why-was-my-intravitreal-injection-claim-denied
9. AAPC. 66821 Essentials: Break YAG Capsulotomies From Cataract Globals. https://www.aapc.com/codes/coding-newsletters/my-ophthalmology-coding-alert/yag-procedures-66821-essentials-break-yag-capsulotomies-from-cataract-globals-108455-article
10. Envolve Vision. OC.UM.CP.0012 Complex Cataract (66982) Criteria. https://visionbenefits.envolvehealth.com/docs/forms/OC.UM.CP.0012-Complex-Cataract.pdf
11. American Academy of Ophthalmology. Coding Resources: Modifier, Global Period, and Diagnostic Test Guidance. https://www.aao.org/practice-management/coding
12. X12.org. Claim Adjustment Reason Codes (CARC) Master List. https://x12.org/codes/claim-adjustment-reason-codes